The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response (Q43993272)

28 November 2017

The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response (English)

1 reference

28 November 2017

Miller V

1

1 reference

28 November 2017

Stark T

series ordinal

2

1 reference

28 November 2017

Loeliger AE

series ordinal

3

1 reference

28 November 2017

Lange JM

series ordinal

4

1 reference

28 November 2017

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

3

1 reference

28 November 2017

2

1 reference

28 November 2017

135-145

1 reference

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

28 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Resistance to HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Lack of pharmacokinetic interaction between nelfinavir and nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2002.00101.X

10.1046/J.1468-1293.2002.00101.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference